Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
National Taiwan University Hospital
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06546475CT.gov A Pilot Trial of Tapering Antipsychotics for Patients in Remitted Psychosis Co-administering With N-Acetylcysteine | — | Not Yet Recruiting | — | — | — |
NCT05796401CT.gov Efficiency of a Composite Personalised Care on Functional Outcome in Early Psychosis | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Psychotic Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Acetylcysteine (this asset) | National Taiwan University Hospital | Approved | BB · 65 |
| Risperidone | Northwell Health | P4 | BBB |
| Olanzapine | Shanghai Jiao Tong University School of Medicine | P4 | BBB |
| Asenapine | Centre de Recherche de l'Institut Universitaire en Santé Mentale de Québec | P4 | BBB |
| Eukystol | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | P4 | BBB |
| Paliperidone | Consorcio Centro de Investigación Biomédica en Red (CIBER) | P4 | BBB |
| Simvastatin | Mclean Hospital | P4 | BBB |
| Sertraline | Northwell Health | P4 | BBB |
| Quetiapine | Shanghai Jiao Tong University School of Medicine | P4 | BBB |
+42 more in the Psychotic Disorder cohort
Other indications for Acetylcysteine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Idiopathic Pulmonary Fibrosis | — | P4 | BBB · 74 |
| Schizophreniform Disorder | — | P4 | BBB · 74 |
| Pulmonary Fibrosis | — | P3 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- RisperidoneNorthwell HealthBBB
- OlanzapineShanghai Jiao Tong University School of MedicineBBB
- AsenapineCentre de Recherche de l'Institut Universitaire en Santé Mentale de QuébecBBB
- EukystolFundación Pública Andaluza para la gestión de la Investigación en SevillaBBB
- PaliperidoneConsorcio Centro de Investigación Biomédica en Red (CIBER)BBB
Citation
Floatz Terminal. Acetylcysteine in Psychotic Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/acetylcysteine-psychotic-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →